Current treatment of type 1 diabetes mellitus (T1DM) depends on the replacement of endogenous insulin by regular subcutaneous injections of exogenous insulin. Unfortunately, exogenous insulin therapy is associated with patient compliance issues and life-threatening hypoglycaemic events. This article by Dr. Lawrence Billing at Mogrify will explore regenerative approaches to resolve T1DM with a focus on how to direct cell reprogramming could influence the field.